Controlled trial of thyrotropin releasing hormone in amyotrophic lateral sclerosis

Neurology. 1986 Feb;36(2):146-51. doi: 10.1212/wnl.36.2.146.

Abstract

A double-blind controlled trial of thyrotropin releasing hormone (TRH) 150 mg IM daily in 30 patients with amyotrophic lateral sclerosis is reported. The drug/placebo was administered for 2 months, followed by a 2-month "wash-out". Evaluation of strength, functional ability, and respiratory functions was performed. A temporary increase in the strength of some muscles was detected following the administration of TRH, but no change in functional performance was noted. Neither the patients nor the investigators believed the effects were of any marked clinical significance. The course of the illness was not altered.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Aged
  • Amyotrophic Lateral Sclerosis / drug therapy*
  • Clinical Trials as Topic
  • Double-Blind Method
  • Electromyography
  • Female
  • Humans
  • Injections, Intramuscular
  • Male
  • Middle Aged
  • Muscles / drug effects
  • Muscles / physiology
  • Random Allocation
  • Thyrotropin-Releasing Hormone / administration & dosage
  • Thyrotropin-Releasing Hormone / adverse effects
  • Thyrotropin-Releasing Hormone / therapeutic use*
  • Time Factors

Substances

  • Thyrotropin-Releasing Hormone